Citations (93)
Keep up to date with the latest research on this topic with citation updates for this article.
Read on this site (19)
Siddharth Sarkar, Rakesh Lal, Mohit Varshney, Saurabh Kumar & Yatan Pal Singh Balhara. (2019) Can Tramadol be Used for Maintenance Treatment of Opioid Dependence?. Substance Use & Misuse 54:3, pages 506-513.
Read now
Read now
William W Stoops & Craig R Rush. (2014) Combination pharmacotherapies for stimulant use disorder: a review of clinical findings and recommendations for future research. Expert Review of Clinical Pharmacology 7:3, pages 363-374.
Read now
Read now
Craig R Rush & William W Stoops. (2012) Agonist Replacement Therapy for Cocaine Dependence: A Translational Review. Future Medicinal Chemistry 4:2, pages 245-265.
Read now
Read now
Jason M White & Olga V Lopatko. (2007) Opioid maintenance: a comparative review of pharmacological strategies. Expert Opinion on Pharmacotherapy 8:1, pages 1-11.
Read now
Read now
KathyT. Breslin & Sandra Malone. (2006) Maintaining the Viability and Safety of the Methadone Maintenance Treatment Program. Journal of Psychoactive Drugs 38:2, pages 157-160.
Read now
Read now
Timothy B. Mitchell, Jason M. White, Andrew A. Somogyi & Felix Bochner. (2006) Switching between Methadone and Morphine for Maintenance Treatment of Opioid Dependence: Impact on Pain Sensitivity and Mood Status. American Journal on Addictions 15:4, pages 311-315.
Read now
Read now
Isabelle Feroni, Patrick Peretti-Watel, Alain Paraponaris, Alain Masut, Eleonore Ronfle, Jean-Claude Mabriez & Jean-Claude Mabriez. (2005) French General Practitioners' Attitudes and Prescription Patterns Toward Buprenorphine Maintenance Treatment. Journal of Addictive Diseases 24:3, pages 7-22.
Read now
Read now
Peter Barglow. (2004) Comparison of VA Intentional and Unintentional Deaths. American Journal on Addictions 13:4, pages 358-371.
Read now
Read now
Jamshid Ahmadi & Mojtaba Ahmadi. (2003) Twelve‐month maintenance treatment of heroin‐dependent outpatients with buprenorphine. Journal of Substance Use 8:1, pages 39-41.
Read now
Read now
Nicholas Lintzeris, Alison Ritter, Adrian Dunlop & Peter Muhleisen. (2002) Training primary health care professionals to prvide Buprenorphine and LAAM treatment. Substance Abuse 23:4, pages 245-254.
Read now
Read now
DanielS. Keller & Helen Dermatis. (1999) Current status of professional training in the addictions. Substance Abuse 20:3, pages 123-140.
Read now
Read now
DavidC. Lewis. (1999) Access to Narcotic Addiction Treatment and Medical Care. Journal of Addictive Diseases 18:2, pages 5-21.
Read now
Read now
Sandra B. Malone & Kathy T. Breslin. (1999) CE Feature: Methadone Maintenance: A Viable Treatment Approach for Chronic Heroin Addiction. Journal of Addictions Nursing 11:4, pages 149-163.
Read now
Read now
HarryW. Haverkos. (1998) HIV/AIDS and Drug Abuse: Epidemiology and Prevention. Journal of Addictive Diseases 17:4, pages 91-103.
Read now
Read now
Craig Jaffe, Katherine Anne Comtois, Donald A. Calsyn & Andrew J. Saxon. (1998) A Pilot Study Comparing Severely and Persistently Mentally III Opiate-Addicted Patients in Dual-Diagnosis Treatment with Patients in Methadone Maintenance. American Journal on Addictions 7:4, pages 288-298.
Read now
Read now
Morton Glanz, Sidney Klawansky, William McAullife & Thomas Chalmers. (1997) Methadone vs. L-alpha-acetylmethadol (LAAM) in the Treatment of Opiate Addiction: A Meta-Analysis of the Randomized, Controlled TriaIs. American Journal on Addictions 6:4, pages 339-349.
Read now
Read now
J. W. De Vos, H. vanWilgenburg, W. Van Den Brink, C. D. Kaplan & M. W. De Vries. (1996) Patterns of Craving and Pharmacokinetics in Long-Term Opiate Addicts in Methadone Maintenance Therapy. Addiction Research 3:4, pages 285-295.
Read now
Read now
Peggy A. Compton, Donald R. Wesson, V. Charles Charuvastra & Walter Ling. (1996) Buprenorphine as a Pharmacotherapy for Opiate Addiction What Dose Provides a Therapeutic Response?. American Journal on Addictions 5:3, pages 220-230.
Read now
Read now
MichaelL. Prendergast, Christine Grella, SusannaM. Perry & M.
Douglas Anglin. (1995) Levo-Alpha-Acetylmethadol (LAAM): Clinical, Research, and Policy Issues of a New Pharmacotherapy for Opioid Addiction. Journal of Psychoactive Drugs 27:3, pages 239-247.
Read now
Read now
Articles from other publishers (74)
Mohammadreza Vafaeinasab, Hamidreza Zare, Ali Dehghani, Seyedehzahra Malek, Maryam Dehghani-Tafti & Mohammadtaghi Sarebanhassanabadi. (2022) Comparison of Lapse Rate in Drug Dependent Patients in 2 Methods of Methadone Maintenance Treatment and Buprenorphine Maintenance Treatment. Substance Abuse: Research and Treatment 16, pages 117822182211125.
Crossref
Crossref
Walter Ling & Steve Shoptaw. 2021. Treating Opioid Use Disorder in General Medical Settings. Treating Opioid Use Disorder in General Medical Settings
9
21
.
Jamshid Ahmadi, EbrahimMoghimi Sarani & MinaSefidfard Jahromi. (2020) Rapid effect of a single-dose buprenorphine on reduction of opioid craving and suicidal ideation: A randomized, double blind, placebo-controlled study. Tzu Chi Medical Journal 32:1, pages 58.
Crossref
Crossref
Jamshid Ahmadi, Mina Sefidfard Jahromi, Dara Ghahremani & Edythe D. London. (2018) Single high-dose buprenorphine for opioid craving during withdrawal. Trials 19:1.
Crossref
Crossref
Yao‐Chang Chiang, Ruey‐Yun Wang, Chieh‐Liang Huang, Shue‐Hwa Chen, Wen‐Jing Ho, Hsien‐Yuan Lane, Ing‐Kang Ho, Hwei‐Ting Yang & Wen‐Lung Ma. (2017) Reduced dosing and liability in methadone maintenance treatment by targeting oestrogen signal for morphine addiction. Journal of Cellular and Molecular Medicine 21:12, pages 3552-3564.
Crossref
Crossref
Jamshid Ahmadi. (2017) Three high doses of buprenorphine in the treatment of prolonged and severe opium dependence: a new access. Journal of Addiction and Dependence 3:1, pages 1-3.
Crossref
Crossref
Walter Ling. (2016) A Perspective on Opioid Pharmacotherapy: Where We Are and How We Got Here. Journal of Neuroimmune Pharmacology 11:3, pages 394-400.
Crossref
Crossref
B. Levi Bolin, William W. Stoops, Jeremy P. Sites & Craig R. Rush. (2016) Abuse Potential of Oral Phendimetrazine in Cocaine-dependent Individuals. Journal of Addiction Medicine 10:3, pages 156-165.
Crossref
Crossref
J Ahmadi. (2016) Fast Treatment of Methamphetamine Related Anxiety and Depressive Disorders: A Novel Approach. Journal of Addiction Medicine and Therapeutic Science, pages 001-003.
Crossref
Crossref
Jamshid Ahmadi. (2016) Comparison of electroconvulsive therapy, buprenorphine and methadone in the management of methamphetamine dependency and withdrawal craving. Journal of Addiction and Dependence 2:4, pages 1-3.
Crossref
Crossref
Jamshid Ahmadi. (2016) Treatment of Chronic Methadone Dependence with Buprenorphine. Journal of Addiction and Dependence 2:3, pages 1-3.
Crossref
Crossref
Jamshid Ahmadi. (2016) Pethidine Abuse: a novel finding. Journal of Addiction and Dependence 2:2, pages 1-3.
Crossref
Crossref
Kevin A. Sevarino & Bryan C. Shelby. 2015. Psychiatry. Psychiatry
1561
1614
.
Robert M. Swift & Elie G. Aoun. (2014) Pharmacotherapy of Alcohol and Drug Dependence. Current Behavioral Neuroscience Reports 2:1, pages 30-39.
Crossref
Crossref
Robert Swift & Lorenzo Leggio. 2013. Terapia uzależnień. Metody oparte na dowodach naukowych. Terapia uzależnień. Metody oparte na dowodach naukowych.
Jose Martinez-Raga, Francisco Gonzalez-Saiz, Julian Oñate, Itziar Oyagüez, Eliazar Sabater & Miguel A Casado. (2012) Budgetary impact analysis of buprenorphine-naloxone combination (Suboxone®) in Spain. Health Economics Review 2:1.
Crossref
Crossref
Joshua A. Lile, Thomas H. Kelly & Lon R. Hays. (2011) Separate and combined effects of the cannabinoid agonists nabilone and Δ9-THC in humans discriminating Δ9-THC. Drug and Alcohol Dependence 116:1-3, pages 86-92.
Crossref
Crossref
Craig R. Rush, William W. Stoops, Joshua A. Lile, Paul E. A. Glaser & Lon R. Hays. (2010) Subjective and physiological effects of acute intranasal methamphetamine during d-amphetamine maintenance. Psychopharmacology 214:3, pages 665-674.
Crossref
Crossref
Joshua A. Lile, Thomas H. Kelly & Lon R. Hays. (2010) Substitution Profile of the Cannabinoid Agonist Nabilone in Human Subjects Discriminating Δ9-Tetrahydrocannabinol. Clinical Neuropharmacology 33:5, pages 235-242.
Crossref
Crossref
Craig R. Rush, William W. Stoops, Rajkamur J. Sevak & Lon R. Hays. (2010) Cocaine Choice in Humans During d-Amphetamine Maintenance. Journal of Clinical Psychopharmacology 30:2, pages 152-159.
Crossref
Crossref
Jason M. White. 2011. Addiction Medicine. Addiction Medicine
1029
1048
.
Andrea Gordon, Mark Hutchinson, Sophie La Vincente, Tim Mitchell, Glynn Morrish, David Newcombe, Andrew Somogyi & Jason White. 2009. Pharmacotherapies for the Treatment of Opioid Dependence. Pharmacotherapies for the Treatment of Opioid Dependence
15
53
.
Craig R. Rush, William W. Stoops & Lon R. Hays. (2009) Cocaine effects during d-amphetamine maintenance: A human laboratory analysis of safety, tolerability and efficacy. Drug and Alcohol Dependence 99:1-3, pages 261-271.
Crossref
Crossref
Robert Swift & Lorenzo Leggio. 2009. Evidence-Based Addiction Treatment. Evidence-Based Addiction Treatment
287
310
.
Lori J Ducharme & Amanda J Abraham. (2008) State policy influence on the early diffusion of buprenorphine in community treatment programs. Substance Abuse Treatment, Prevention, and Policy 3:1.
Crossref
Crossref
Lisa R. Gerak, Ruggero Galici & Charles P. France. (2008) Self administration of cocaine in monkeys receiving LAAM acutely or chronically. Physiology & Behavior 93:1-2, pages 20-26.
Crossref
Crossref
Richard B. Rothman, Bruce E. Blough & Michael H. Baumann. 2008. Drug Addiction. Drug Addiction
311
326
.
Richard B. Rothman, Bruce E. Blough & Michael H. Baumann. (2007) Dual dopamine/serotonin releasers as potential medications for stimulante and alcohol addictions. The AAPS Journal 9:1, pages E1-E10.
Crossref
Crossref
RICHARD B. ROTHMAN & MICHAEL H. BAUMANN. (2006) Balance between Dopamine and Serotonin Release Modulates Behavioral Effects of Amphetamine‐Type Drugs. Annals of the New York Academy of Sciences 1074:1, pages 245-260.
Crossref
Crossref
S. Popova, J. Rehm & B. Fischer. (2006) An overview of illegal opioid use and health services utilization in Canada. Public Health 120:4, pages 320-328.
Crossref
Crossref
G. Alan Marlatt & Katie Witkiewitz. 2006. Practitioner’s Guide to Evidence-Based Psychotherapy. Practitioner’s Guide to Evidence-Based Psychotherapy
694
705
.
Douglas Longshore, Jeffrey Annon, M. Douglas Anglin & Richard A. Rawson. (2005) Levo‐alpha‐acetylmethadol (LAAM) versus methadone: treatment retention and opiate use. Addiction 100:8, pages 1131-1139.
Crossref
Crossref
David A.L. Newcombe, Felix Bochner, Jason M. White & Andrew A. Somogyi. (2004) Evaluation of levo-alpha-acetylmethdol (LAAM) as an alternative treatment for methadone maintenance patients who regularly experience withdrawal: a pharmacokinetic and pharmacodynamic analysis. Drug and Alcohol Dependence 76:1, pages 63-72.
Crossref
Crossref
Shaunteng He & Kenneth Grasing. (2004) Chronic opiate treatment enhances both cocaine-reinforced and cocaine-seeking behaviors following opiate withdrawal. Drug and Alcohol Dependence 75:2, pages 215-221.
Crossref
Crossref
Jamshid Ahmadi, Mohammadali Babaee-Beigi, Mohammadjavad Alishahi, Iraj Maany & Taghi Hidari. (2004) Twelve-month maintenance treatment of opium-dependent patients. Journal of Substance Abuse Treatment 26:1, pages 61-64.
Crossref
Crossref
Enno FreyeEnno Freye. 2004. Opioide in der Medizin. Opioide in der Medizin
371
377
.
Enno FreyeEnno Freye. 2004. Opioide in der Medizin. Opioide in der Medizin
357
370
.
Enno FreyeEnno Freye. 2004. Opioide in der Medizin. Opioide in der Medizin
325
356
.
Enno FreyeEnno Freye. 2004. Opioide in der Medizin. Opioide in der Medizin
323
324
.
Enno FreyeEnno Freye. 2004. Opioide in der Medizin. Opioide in der Medizin
311
322
.
Thomas R. Kosten. (2003) Buprenorphine for Opioid Detoxification. Addictive Disorders & Their Treatment 2:4, pages 107-112.
Crossref
Crossref
Richard B. Rothman & Michael H. Baumann. (2003) Monoamine transporters and psychostimulant drugs. European Journal of Pharmacology 479:1-3, pages 23-40.
Crossref
Crossref
Timothy B Mitchell, Jason M White, Andrew A Somogyi & Felix Bochner. (2003) Comparative pharmacodynamics and pharmacokinetics of methadone and slow-release oral morphine for maintenance treatment of opioid dependence. Drug and Alcohol Dependence 72:1, pages 85-94.
Crossref
Crossref
Jamshid Ahmadi. (2003) Methadone versus buprenorphine maintenance for the treatment of heroin-dependent outpatients. Journal of Substance Abuse Treatment 24:3, pages 217-220.
Crossref
Crossref
Francesco Leri, Julie Bruneau & Jane Stewart. (2002) Understanding polydrug use: review of heroin and cocaine co‐use. Addiction 98:1, pages 7-22.
Crossref
Crossref
M.D. Baño rodrigo, M.L. López garcía & J.L. Guillén llera. (2003) De metadona a buprenorfina. La inducción del tratamiento. Trastornos Adictivos 5:4, pages 295-302.
Crossref
Crossref
Jamshid Ahmadi & Nasrin Bahrami. (2002) Buprenorphine treatment of opium-dependent outpatients seeking treatment in Iran. Journal of Substance Abuse Treatment 23:4, pages 415-417.
Crossref
Crossref
Philip S. Mehler. (2002) Treating Opioid Dependence: Growing Implications for Primary Care. Primary Care Case Reviews 5:3, pages 132-139.
Crossref
Crossref
RICHARD B. ROTHMAN, BRUCE E. BLOUGH & MICHAEL H. BAUMANN. (2006) Appetite Suppressants as Agonist Substitution Therapies for Stimulant Dependence. Annals of the New York Academy of Sciences 965:1, pages 109-126.
Crossref
Crossref
Jamshid Ahmadi. (2002) A Randomized, Clinical Trial of Buprenorphine Maintenance Treatment for Iranian Patients With Opioid Dependency. Addictive Disorders & Their Treatment 1:1, pages 25-27.
Crossref
Crossref
Timothy W. Kinlock, Robert J. Battjes & Robert P. Schwartz. (2002) A novel opioid maintenance program for prisoners: preliminary findings. Journal of Substance Abuse Treatment 22:3, pages 141-147.
Crossref
Crossref
Jamshid Ahmadi. (2002) Buprenorphine maintenance treatment of heroin dependence: the first experience from Iran. Journal of Substance Abuse Treatment 22:3, pages 157-159.
Crossref
Crossref
Jamshid Ahmadi. (2002) A controlled trial of buprenorphine treatment for opium dependence: the first experience from Iran. Drug and Alcohol Dependence 66:2, pages 111-114.
Crossref
Crossref
Jody L SindelarDavid A Fiellin. (2001) Innovations in Treatment for Drug Abuse: Solutions to a Public Health Problem. Annual Review of Public Health 22:1, pages 249-272.
Crossref
Crossref
Henry Sershen, Audrey Hashim & Abel Lajtha. 2001.
115
133
.
Steven L West, Keri K O'Neal & Carolyn W Graham. (2000) A meta-analysis comparing the effectiveness of buprenorphine and methadone. Journal of Substance Abuse 12:4, pages 405-414.
Crossref
Crossref
C J Evans, G Monteillet-Agius, N Saliminejad & P A Zaki. (2000) Opiate drugs: ‘guilt by association’. Molecular Psychiatry 5:2, pages 122-123.
Crossref
Crossref
T. Poehlke. 2000. Drogen. Drogen
71
98
.
Sarah Welch & John Strang. (2018) Pharmacotherapy in the treatment of drug dependence: options to strengthen effectiveness. Advances in Psychiatric Treatment 5:6, pages 427-434.
Crossref
Crossref
Rajneesh P. Nath, Robert A. Upton, E. Thomas Everhart, Polly Cheung, Peter Shwonek, Reese T. Jones & John E. Mendelson. (2013) Buprenorphine Pharmacokinetics: Relative Bioavailability of Sublingual Tablet and Liquid Formulations. The Journal of Clinical Pharmacology 39:6, pages 619-623.
Crossref
Crossref
Robert M Swift. (1998) Pharmacologic Treatments for Drug and Alcohol Dependence: Experimental and Standard Therapies. Psychiatric Annals 28:12, pages 697-702.
Crossref
Crossref
Craig Jaffe, Katherine Anne Comtois, Donald A. Calsyn & Andrew J. Saxon. (2010) A Pilot Study Comparing Severely and Persistently Mentally III Opiate‐Addicted Patients in Dual‐Diagnosis Treatment With Patients in Methadone Maintenance. The American Journal on Addictions 7:4, pages 288-298.
Crossref
Crossref
Elinore F. McCance-Katz, Petrie M. Rainey, Peter Jatlow & Gerald Friedland. (1998) Methadone Effects on Zidovudine Disposition (AIDS Clinical Trials Group 262). Journal of Acquired Immune Deficiency Syndromes and Human Retrovirology 18:5, pages 435-443.
Crossref
Crossref
John Marsden, Michael Gossop, Michael Farrell & John Strang. (1998) Opioid Substitution: Critical Issues and Future Directions. Journal of Drug Issues 28:1, pages 243-263.
Crossref
Crossref
Linda A. Dimeff & G. Alan Marlatt. (1998) Preventing relapse and maintaining change in addictive behaviors.. Clinical Psychology: Science and Practice 5:4, pages 513-525.
Crossref
Crossref
Yunkai Yu, Li Zhang, Xixi Yin, Hui Sun, George R. Uhl & Jia Bei Wang. (1997) μ Opioid Receptor Phosphorylation, Desensitization, and Ligand Efficacy. Journal of Biological Chemistry 272:46, pages 28869-28874.
Crossref
Crossref
Morton Glanz, Sidney Klawansky, William McAullife & Thomas Chalmers. (2010) Methadone vs. L‐alpha‐acetylmethadol (LAAM) in the Treatment of Opiate Addiction. The American Journal on Addictions 6:4, pages 339-349.
Crossref
Crossref
John Mendelson, Reese T. Jones, Susette Welm, James Brown & Steven L. Batki. (1997) Buprenorphine and naloxone interactions in methadone maintenance patients. Biological Psychiatry 41:11, pages 1095-1101.
Crossref
Crossref
John Mendelson, Robert A. Upton, E. Thomas Everhart, Peyton Jacob III & Reese T. Jones. (2013) Bioavailability of Sublingual Buprenorphine. The Journal of Clinical Pharmacology 37:1, pages 31-37.
Crossref
Crossref
Mary Jeanne Kreek. (1997) Clinical Update of Opioid Agonist and Partial Agonist Medications for the Maintenance Treatment of Opioid Addiction. Seminars in Neuroscience 9:3-4, pages 140-157.
Crossref
Crossref
Gery Schulteis, Lisa H. Gold & George F. Koob. (1997) Preclinical Behavioral Models for Addressing Unmet Needs in Opiate Addiction. Seminars in Neuroscience 9:3-4, pages 94-109.
Crossref
Crossref
Patrick G. O'Connor & Jeffrey H. Samet. (1996) The substance-using human immunodeficiency virus patient: Approaches to outpatient management. The American Journal of Medicine 101:4, pages 435-444.
Crossref
Crossref
Peggy A. Compton, Donald R. Wesson, V. Charles Charuvastra & Walter Ling. (2010)
Buprenorphine as a Pharmacotherapy for Opiate Addiction:
What Dose Provides a Therapeutic Response?
. The American Journal on Addictions 5:3, pages 220-230.
Crossref
Crossref
John Mendelson, Reese T. Jones, Isabella Fernandez, Susette Welm, Ann K. Melby & Matthew J. Baggott. (1996) Buprenorphine and naloxone interactions in opiate-dependent volunteers*. Clinical Pharmacology & Therapeutics 60:1, pages 105-114.
Crossref
Crossref